Development
AbCellera Biologics Inc.
ABCL
$4.59
$0.092.00%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -64.80% | 6.28% | 23.89% | -34.18% | -212.28% |
| Total Depreciation and Amortization | 22.95% | 2.11% | 1.91% | 2.30% | 3.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.13% | -10.68% | 31.79% | -52.36% | 61.84% |
| Change in Net Operating Assets | -80.32% | -74.04% | 220.33% | -179.03% | 116.52% |
| Cash from Operations | -18,400.94% | -100.53% | 145.17% | -242.54% | 124.38% |
| Capital Expenditure | 29.02% | 25.26% | -81.53% | -21.52% | 1.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -231.11% | 204.95% | 94.66% | -2,744.39% | 98.24% |
| Cash from Investing | -90.23% | 62.82% | 77.01% | -776.80% | 93.95% |
| Total Debt Issued | -43.59% | 4,631.08% | -69.80% | 40.40% | 51.08% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 50.27% | -237.27% | 128.59% | -- | 100.00% |
| Cash from Financing | -43.21% | 1,482.34% | 191.48% | -231.23% | 1,936.84% |
| Foreign Exchange rate Adjustments | 200.47% | -233.38% | 474.18% | -158.52% | 104.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -433.80% | 44.80% | 93.17% | -1,434.59% | 103.49% |